NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,857 | -71.4% | 6,475 | -72.4% | 0.00% | – |
| Q2 2023 | $13,496 | -68.7% | 23,463 | -61.8% | 0.00% | – |
| Q1 2023 | $43,178 | -94.8% | 61,428 | -83.2% | 0.00% | -100.0% |
| Q4 2022 | $827,617 | +26.2% | 366,202 | +78.7% | 0.01% | +25.0% |
| Q3 2022 | $656,000 | -34.2% | 204,913 | -21.9% | 0.00% | -33.3% |
| Q2 2022 | $997,000 | -79.3% | 262,259 | -70.6% | 0.01% | -85.4% |
| Q1 2022 | $4,812,000 | -32.3% | 892,842 | +69.6% | 0.04% | -39.7% |
| Q4 2021 | $7,111,000 | +160.9% | 526,349 | +246.7% | 0.07% | +100.0% |
| Q3 2021 | $2,726,000 | +150.6% | 151,797 | +139.3% | 0.03% | +183.3% |
| Q2 2021 | $1,088,000 | -49.5% | 63,425 | -41.1% | 0.01% | -57.1% |
| Q1 2021 | $2,155,000 | -14.2% | 107,736 | -27.1% | 0.03% | -20.0% |
| Q4 2020 | $2,511,000 | +78.5% | 147,723 | +74.2% | 0.04% | +66.7% |
| Q3 2020 | $1,407,000 | -26.4% | 84,789 | +2.7% | 0.02% | -36.4% |
| Q2 2020 | $1,911,000 | +210.2% | 82,530 | +139.1% | 0.03% | +94.1% |
| Q1 2020 | $616,000 | -37.5% | 34,517 | -24.3% | 0.02% | -5.6% |
| Q4 2019 | $985,000 | +74.6% | 45,615 | +47.4% | 0.02% | +63.6% |
| Q3 2019 | $564,000 | -84.2% | 30,950 | -69.1% | 0.01% | -83.1% |
| Q2 2019 | $3,563,000 | -7.5% | 100,133 | -12.6% | 0.06% | -48.0% |
| Q1 2019 | $3,851,000 | +1825.5% | 114,622 | +3386.1% | 0.12% | +1036.4% |
| Q3 2018 | $200,000 | -41.9% | 3,288 | -53.3% | 0.01% | -35.3% |
| Q2 2018 | $344,000 | -92.5% | 7,045 | -83.6% | 0.02% | -93.7% |
| Q1 2018 | $4,569,000 | +884.7% | 43,000 | +59.1% | 0.27% | +793.3% |
| Q3 2016 | $464,000 | +174.6% | 27,021 | +126.9% | 0.03% | +200.0% |
| Q2 2016 | $169,000 | +525.9% | 11,911 | +500.7% | 0.01% | +400.0% |
| Q1 2016 | $27,000 | -96.0% | 1,983 | -95.1% | 0.00% | -95.0% |
| Q4 2015 | $682,000 | +239.3% | 40,500 | +120.3% | 0.04% | +300.0% |
| Q3 2015 | $201,000 | -77.3% | 18,381 | -74.0% | 0.01% | -76.7% |
| Q2 2015 | $886,000 | +76.8% | 70,832 | +119.1% | 0.04% | +59.3% |
| Q4 2014 | $501,000 | +10.8% | 32,326 | -13.6% | 0.03% | -3.6% |
| Q3 2014 | $452,000 | +8.7% | 37,409 | +15.3% | 0.03% | +12.0% |
| Q2 2014 | $416,000 | – | 32,436 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |